Pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US. Positive feedback from world-leading glaucoma surgeons involved in the trial. MINIject is the only commercially available MIGS device targeting the supraciliary space. Commercial rollout continues following European approval in 2021
MINIject is currently being investigated in iSTAR Medical’s pivotal STAR-V study, which was approved by the United States Food and Drug Administration (FDA) in July 2021,
The STAR-V trial evaluates MINIject’s efficacy by the mean reduction in eye pressure, as well as the proportion of patients achieving at least a 20 percent reduction in eye pressure notes iSTAR Medical.
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.
